ISRCTN52157196 https://doi.org/10.1186/ISRCTN52157196

# MYELOMA VIIIth trial

| | | |
|---|---|---|
| **Submission date**<br>25/10/2000 | **Recruitment status**<br>No longer recruiting | [ ] Prospectively registered<br>[ ] Protocol |
| **Registration date**<br>25/10/2000 | **Overall study status**<br>Completed | [ ] Statistical analysis plan<br>[ ] Results |
| **Last Edited**<br>27/09/2019 | **Condition category**<br>Cancer | [ ] Individual participant data<br>[ ] Record updated in last year |

**Plain English summary of protocol**
Not provided at time of registration

## Contact information

**Type(s)**
Scientific

**Contact name**
Dr Mark Drayson

**Contact details**
Department of Immunology
Medical School
University of Birmingham
Vincent Drive
Birmingham
United Kingdom
B15 2TT
-
m.t.drayson@bham.ac.uk

## Additional identifiers

**Protocol serial number**
G8003737 expired Oct 99

## Study information

**Scientific Title**
MYELOMA VIIIth trial

**Acronym**

MYELOMA VIIIth trial

### Study objectives
To compare, for survival, the induction of first plateau phase in previously untreated patients with multiple myeloma, the efficacy of the above two treatments

### Ethics approval required
Old ethics approval format

### Ethics approval(s)
Not provided at time of registration.

### Study design
Randomised controlled trial

### Primary study design
Interventional

### Study type(s)
Treatment

### Health condition(s) or problem(s) studied
Leukaemia

### Interventions
All patients receive three courses of ABCM. They are then randomised to continue with ABCM or to change to oral weekly cyclophosphamide.

### Intervention Type
Drug

### Phase
Not Specified

### Drug/device/biological/vaccine name(s)
Cyclophosphamide and ABCM

### Primary outcome(s)
1. Survival
2. Obtaining plateau (stable disease with no more than minimal symptoms)
3. Quality of life

### Key secondary outcome(s))
Not provided at time of registration

### Completion date
01/11/2000

## Eligibility

### Key inclusion criteria
1. Greater than 65 years old and less than 75 years old
2. Myeloma
3. No previous cytotoxic therapy
4. Netrophil count greater than or equal to 1.3 x 10^9/l
5. Platelet count greater than or equal to 75 x 10^9/L
6. Able to tolerate 3 l of fluid per day
7. Apyrexial
8. Free from infection
9. Informed consent

### Participant type(s)
Patient

### Healthy volunteers allowed
No

### Age group
Senior

### Sex
Not Specified

### Key exclusion criteria
Patients with equivocal myelomatosis

### Date of first enrolment
01/11/1993

### Date of final enrolment
01/11/2000

## Locations

### Countries of recruitment
United Kingdom

England

### Study participating centre
**Department of Immunology**
Birmingham
United Kingdom
B15 2TT

## Sponsor information

**Organisation**
Medical Research Council (MRC) (UK)

# Funder(s)

**Funder type**
Research council

**Funder Name**
Medical Research Council (MRC) (UK)

**Alternative Name(s)**
Medical Research Council (United Kingdom), UK Medical Research Council, MRC

**Funding Body Type**
Government organisation

**Funding Body Subtype**
National government

**Location**
United Kingdom

# Results and Publications

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**
Not provided at time of registration